blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3898679

EP3898679 - POLYPEPTIDES [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  24.09.2021
Database last updated on 31.08.2024
FormerThe international publication has been made
Status updated on  02.07.2020
Formerunknown
Status updated on  08.01.2020
Most recent event   Tooltip19.12.2023New entry: Renewal fee paid 
Applicant(s)For all designated states
Alligator Bioscience AB
Medicon Village
Scheelevägen 2
223 81 Lund / SE
[2021/43]
Inventor(s)01 / SÄLL, Anna
Alligator Bioscience AB
Medicon Village
Scheelevägen 2
223 81 Lund / SE
02 / ELLMARK, Peter
Alligator Bioscience AB
Medicon Village
Scheelevägen 2
223 81 Lund / SE
03 / DERONIC, Adnan
Alligator Bioscience AB
Medicon Village
Scheelevägen 2
223 81 Lund / SE
04 / CARLSSON, Fredrika
Alligator Bioscience AB
Medicon Village
Scheelevägen 2
223 81 Lund / SE
05 / HÄGERBRAND, Karin
Alligator Bioscience AB
Medicon Village
Scheelevägen 2
223 81 Lund / SE
06 / VON SCHANTZ, Laura
Alligator Bioscience AB
Medicon Village
Scheelevägen 2
223 81 Lund / SE
 [2021/43]
Representative(s)Potter Clarkson
Chapel Quarter
Mount Street
Nottingham NG1 6HQ / GB
[N/P]
Former [2021/43]Potter Clarkson
The Belgrave Centre
Talbot Street
Nottingham NG1 5GG / GB
Application number, filing date19828547.017.12.2019
[2021/43]
WO2019EP85786
Priority number, dateGB2018002055617.12.2018         Original published format: GB 201820556
GB2019000546717.04.2019         Original published format: GB 201905467
GB2019001001612.07.2019         Original published format: GB 201910016
[2021/43]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2020127374
Date:25.06.2020
Language:EN
[2020/26]
Type: A2 Application without search report 
No.:EP3898679
Date:27.10.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 25.06.2020 takes the place of the publication of the European patent application.
[2021/43]
Search report(s)International search report - published on:EP29.10.2020
ClassificationIPC:C07K16/28, C07K16/30, A61P35/00, A61K39/00, C07K16/32
[2021/43]
CPC:
C07K16/2878 (EP,CN,US); C07K16/3092 (US); A61K39/3955 (US);
A61K45/06 (US); A61P35/00 (CN,US); A61P35/02 (CN);
C07K16/2803 (US); C07K16/2851 (EP,US); C07K16/2863 (US);
C07K16/2866 (US); C07K16/2887 (US); C07K16/30 (EP,CN,US);
C07K16/3007 (US); C07K16/3015 (US); C07K16/32 (EP);
G01N33/56966 (CN); G01N33/57488 (CN); G01N33/57492 (US);
A61K2039/505 (EP,CN,US); C07K2317/21 (US); C07K2317/31 (EP,CN,US);
C07K2317/55 (US); C07K2317/56 (CN,US); C07K2317/565 (CN);
C07K2317/569 (CN,US); C07K2317/622 (CN,US); C07K2317/624 (CN);
C07K2317/73 (CN); C07K2317/732 (CN); C07K2317/734 (CN);
C07K2317/75 (EP); C07K2317/77 (EP); C07K2317/92 (EP,CN) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/43]
TitleGerman:POLYPEPTIDE[2021/43]
English:POLYPEPTIDES[2021/43]
French:POLYPEPTIDES[2021/43]
Entry into regional phase13.07.2021National basic fee paid 
13.07.2021Designation fee(s) paid 
13.07.2021Examination fee paid 
Examination procedure13.07.2021Examination requested  [2021/43]
13.07.2021Date on which the examining division has become responsible
01.02.2022Amendment by applicant (claims and/or description)
Fees paidRenewal fee
08.12.2021Renewal fee patent year 03
13.12.2022Renewal fee patent year 04
19.12.2023Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XI]US2018194862  (AKAMATSU YOSHIKO [US], et al) [X] 1-3,79,80,84,86,90-92,104-109 * the whole document * [I] 4-68,81-83,85,87-89,93-103;
 [XP]WO2019093342  (KYOWA HAKKO KIRIN CO LTD [JP]) [XP] 1-68,79-109 * the whole document *
 [XI]  - BUSHRA HUSAIN ET AL, "Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies", BIODRUGS, NZ, (20180821), vol. 32, no. 5, doi:10.1007/s40259-018-0299-9, ISSN 1173-8804, pages 441 - 464, XP055678494 [X] 1-3,79,80,84,86,90-92,104-109 * the whole document * [I] 4-68,81-83,85,87-89,93-103

DOI:   http://dx.doi.org/10.1007/s40259-018-0299-9
 [XI]  - Anonymous, "AbbVie R&D Day Forward-Looking Statements and Non-GAAP Financial Information", (20160101), URL: https://investors.abbvie.com/static-files/4c774749-25a8-4c8d-939d-3a3cdc45c8d6, (20200322), XP055678496 [X] 1-3,79,80,84,86,90-92,104-109 * the whole document * [I] 4-68,81-83,85,87-89,93-103
 [XI]  - E Dahlen ET AL, "Therapeutic Advances in Vaccines and Immunotherapy Bispecific antibodies in cancer immunotherapy", Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/2515135518763280Therapeutic, (20180301), pages 3 - 17, URL: https://journals.sagepub.com/doi/pdf/10.1177/2515135518763280, (20200322), XP055678495 [X] 1-3,79,80,84,86,90-92,104-109 * the whole document * [I] 4-68,81-83,85,87-89,93-103

DOI:   http://dx.doi.org/10.1177/2515135518763280Therapeutic
by applicantUS2010021483
 US4816567
 US2012251531
 US7557190
 US6235883
 US4235871
 US5851451
 EP0213303
    - NYGREN, FEBS J, (20080000), vol. 275, pages 2668 - 2676
    - Innovations Pharmac. Technol., (20060000), pages 27 - 30
    - Meth. Mol. Biol., (20070000), vol. 352, pages 95 - 109
    - Drug Discovery Today, (20050000), vol. 10, pages 23 - 33
    - Nat. Biotechnol., (20040000), vol. 22, pages 575 - 582
    - Nat. Biotechnol., (20050000), vol. 23, pages 1556 - 1561
    - FEBS J, (20070000), vol. 274, pages 86 - 95
    - Expert. Opin. Biol. Ther., (20050000), vol. 5, pages 783 - 797
    - J. Pharmacol. Exp. Ther., (20060000), vol. 318, pages 803 - 809
    - Trends. Biotechnol., (20050000), vol. 23, pages 514 - 522
    - XU et al., mAbs, (20150000), vol. 7, no. 1, pages 231 - 242
 GB20180020556
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.